Impact of prognostic factors on survival rates in patients with ovarian carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 15, 2014, Pages 6087-6094

  Arikan, Sevim Kalsen ^a   Kasap, Burcu ^b   Yetimalar, Hakan ^a   Yildiz, Askin ^a   Sakarya, Derya Kilic ^a   Tatar, Sumeyra ^c  

^a ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^c SIFA UNIVERSITY   (Turkey)

Author keywords

Ovarian cancer; Prognostic factors; Survival analysis; Turkey

Indexed keywords

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CANCER GRADING; CANCER STAGING; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84906247330     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.15.6087     Document Type: Article

References (46)

1. Abe A, Furumoto H, Irahara M, et al (2010). The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer. J Obstet Gynaecol Res, 36, 1023-30.
2. Bosze P, Bast RC, Berchuck A, et al (2000). Conseusus statements on prognostic factors in epithelial ovarian carcinoma. report of the consensus meeting organized by the european society of gynaecological oncology, ESGO. Eur J Gynaecol Oncol, 21, 513-26.
3. Braem MG, Onland-Moret NC, van den Brandt PA, et al (2010). Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol, 172, 1181-9.
4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20, 1248-59.
5. Chan JK, Loizzi V, Lin YG, et al (2003). Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important? Obstet Gynecol, 102, 156-61.
6. Chan JK, Cheung MK, Husain A, et al (2006). Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol, 108, 521-8.
7. Chan JK, Loizzi V, Lin YG, et al (2006). Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer, 95, 1314-20.
8. Chi DS, Eisenhauer EL, Lang J, et al (2006). What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol Oncol, 103, 559-64.
9. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF (2001). A prognostic model for ovarian cancer. Br J Cancer, 85, 944-52.
10. Cooper BC, Sood AK, Davis CS, et al (2002). Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol, 100, 59-64.
11. Coussy F, Chereau E, Darai E, et al (2011). Interest of CA 125 level in management of ovarian cancer. Gynecol Obstet Fertil, 39, 296-301.
12. Creasman WT, Rutledge F (1971). The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol, 110, 773-81.
13. Du Bois A, Reuss A, Pujade-Lauraine E, et al (2009). Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer, 115, 1234-44.
14. Du Bois A, Rochon J, Lamparter C, Pfisterer J; AGO Organkommission OVAR PFisterer (2005). Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer, 15, 183-91.
15. Duffy MJ, Bonfrer JM, Kulpa J, et al (2005). CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Cancer, 15, 679-91.
16. Eisenkop SM, Spirtos NM, Friedman RL, et al (2003). Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol, 90, 390-6.
17. Gaemmaghami F, YousefiZ, Gilani M, Mosavi A, Shariat M (2011). Role of appropriate surgery in survival of patients with epithelial ovarian cancer. Asian Pac J Cancer Prev, 12, 253-7.
18. Gerestein CG, Eijkemans MJ, de Jong D, et al (2009). The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG, 116, 372-80.
19. Gertig D, Hunter D (2002). Ovarian cancer. In: Adami H, Hunter D, Trichopoulos D, eds. Textbook of cancer epidemiology. Oxford: Oxford University Press, 378-99.
20. Griffiths CT (1975). Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr, 42, 101-4.
21. Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009). The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet, 279, 53-6.
22. Heintz AP, Odicino F, Maisonneuve P, et al (2006). Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet, 95, 161-92.
23. Hogberg T, Carstensen J, Simonsen E (1993). Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol, 48, 38-49.
24. Hoskins WJ, McGuire WP, Brady MF, et al (1994). The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol, 170, 974-9.
25. International Federation of Gynecology and Obstetrics (FIGO) (1987). Changes in definition of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol, 56, 263-4.
26. Keettel WC, Pixley E (1958). Diagnostic value of peritoneal washings. Clin Obstet Gynecol, 1, 592-606.
27. Li AJ, Madden AC, Cass I, et al (2004). The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol, 92, 211-4.
28. Li LN, Zhou X, Gu Y, Yan J (2013). Prognostic value of MMP-9 in ovarian cancer: a meta-analysis. Asian Pac J Cancer Prev, 14, 4107-13.
29. Liu XH, Man YN, Wu XZ (2014). Recurrence season impacts the survival of epithelial ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1627-32.
30. Makar AP, Baekelandt M, Trope CG, Kristensen GB (1995). The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol, 56, 175-80.
31. Matei MC, Caruntu ID, Negura L, et al (2010). The assessment of relations between main histologic type of ovarian cancer and some risk and prognostic factors. Rev Med Chir Soc Med Nat Iasi, 114, 1135-41.
32. Meyer T, Rustin GJ (2000). Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer, 82, 1535-8.
33. Mizuno M, Kikkawa F, Shibata K, et al (2003). Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology, 65, 29-36.
34. Moore DH, Kauderer JT, Bell J, Curtin JP, Van Le L (2004). An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a gynecologic oncology group study. Gynecol Oncol, 94, 368-74.
35. Morton DG, Moore JG, Chang N (1961). The clinical value of peritoneal lavage for cytologic examination. Am J Obstet Gynecol, 81, 1115-25.
36. Panici PB, Maggioni A, Hacker N, et al (2005). Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst, 97, 560-6.
37. Riman T, Persson I, Nilsson S (1998). Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol, 49, 695-707.
38. Riman T, Nilsson S, Persson IR (2004). Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand, 83, 783-95.
39. Salet-Lizee D, Alsary S (2008). (The place of lumo-aortic and pelvic lymph node dissection in the treatment of ovarian cancer). J Chir (Paris), 145, 45-49.
40. Salzman J, Marinelli RJ, Wang PL, et al (2011). ESRRAC11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol, 9, 1001156.
41. Sankaranarayanan R, Ferlay J (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol, 20, 207-25.
42. Tang L, Zheng M, Xiong Y, Ding H, Liu FY (2008). Clinical characteristics and prognosis of epithelial ovarian cancer in young women. Ai Zheng, 27, 951-5.
43. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B (2003). Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol, 101, 885-91.
44. Vergote I, De Brabanter J, Fyles A, et al (2001). Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet, 357, 176-182.
45. Wan WN, Zhang YX, Wang XM, et al (2014). ATAD2 is highly expressed in ovarian carcinomas and indicates poor prognosis. Asian Pac J Cancer Prev, 15, 2777-83.
46. Zuna RE, Behrens A (1996). Peritoneal washing cytology in gynecologic cancers: long-term follow-up of 355 patients. J Natl Cancer Inst, 88, 980-7.